ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Desloratadine: Pediatric drug information

Desloratadine: Pediatric drug information
(For additional information see "Desloratadine: Drug information" and see "Desloratadine: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Clarinex
Therapeutic Category
  • Antihistamine
Dosing: Pediatric
Allergic rhinitis, perennial

Allergic rhinitis, perennial: Oral:

Infants 6 to ≤11 months: 1 mg once daily.

Children ≤5 years: 1.25 mg once daily.

Children 6 to ≤11 years: 2.5 mg once daily.

Children ≥12 years and Adolescents: 5 mg once daily.

Allergic rhinitis, seasonal

Allergic rhinitis, s easonal: Oral:

Children 2 to ≤5 years: 1.25 mg once daily.

Children 6 to ≤11 years: 2.5 mg once daily.

Children ≥12 years and Adolescents: 5 mg once daily.

Urticaria, chronic idiopathic

Urticaria, chronic idiopathic: Oral:

Infants 6 to ≤11 months: 1 mg once daily.

Children ≤5 years: 1.25 mg once daily.

Children 6 to ≤11 years: 2.5 mg once daily.

Children ≥12 years and Adolescents: 5 mg once daily.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling for pediatric patients (has not been studied); based on adult information, dosage adjustment may be necessary.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling for pediatric patients (has not been studied); based on adult information, dosage adjustment may be necessary.

Dosing: Adult

(For additional information see "Desloratadine: Drug information")

Allergic rhinitis, perennial or seasonal

Allergic rhinitis, perennial or seasonal: Oral: 5 mg once daily.

Angioedema, acute allergic or recurrent idiopathic

Angioedema, acute allergic or recurrent idiopathic (off-label use):

Note: Not indicated for angioedema associated with anaphylaxis; use epinephrine if anaphylaxis symptoms are present (ie, risk of airway or cardiovascular compromise) (James 2017; Zuraw 2022).

Oral: 5 mg once or twice daily; may increase up to 10 mg twice daily (Cicardi 2014; James 2017; Zuraw 2022).

Urticaria, new onset and chronic spontaneous

Urticaria, new onset (off-label use) and chronic spontaneous (labeled use):

New onset: Oral: Initial: 5 mg once daily. If symptom control is inadequate, may immediately increase to 5 mg twice daily (Asero 2021).

Chronic spontaneous: Oral: Initial: 5 mg once daily. If symptom control is inadequate, may increase in 5 mg/day increments every 1 to 4 weeks up to 10 mg twice daily; periodically reevaluate necessity for continued treatment (EAACI [Zuberbier 2018]; Khan 2021; Staevska 2010).

Urticaria, nonsteroidal anti-inflammatory drug associated, prophylaxis

Urticaria, nonsteroidal anti-inflammatory drug associated, prophylaxis (off-label use): Oral: 5 mg 30 minutes before intake of a strong COX-1 inhibitor (Trautmann 2016).

Dosing: Kidney Impairment: Adult

Moderate to severe impairment: No dosage adjustment necessary; use with caution in severe impairment. Although the US manufacturer’s labeling recommends a dose reduction to 5 mg every other day in patients with mild to severe renal impairment, the increased exposure (Cmax and AUC) observed in single- and multiple-dose pharmacokinetic studies is not considered clinically relevant (Aerius Canadian product monograph 2019; Aerius Netherlands prescribing information 2018; Geha 2001).

Hemodialysis: Poorly dialyzable: No dosage adjustment necessary; use with caution. Although the US manufacturer’s labeling recommends a dose reduction to 5 mg every other day in patients on dialysis, the increased exposure (Cmax and AUC) observed in single- and multiple-dose pharmacokinetic studies is not considered clinically relevant (Aerius Canadian product monograph 2019; Aerius Netherlands prescribing information 2018; Geha 2001).

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary; use with caution in severe impairment. Although the US manufacturer’s labeling recommends a dose reduction to 5 mg every other day in patients with mild to severe hepatic impairment, the increased exposure (Cmax and AUC) observed in single- and multiple-dose pharmacokinetic studies is not considered clinically relevant (Aerius Canadian product monograph 2019; Geha 2001).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults unless otherwise indicated.

>10%:

Gastrointestinal: Diarrhea (infants and children: 15% to 20%)

Nervous system: Headache (14%), irritability (infants: 12%)

Respiratory: Cough (infants and children: 11%), upper respiratory tract infection (infants and children: 11% to 21%)

Miscellaneous: Fever (infants and children: 5% to 17%)

1% to 10%:

Dermatologic: Erythema of skin (infants: 3%), maculopapular rash (children: 3%)

Gastrointestinal: Anorexia (infants: 5%), dyspepsia (3%), increased appetite (children: 3%), nausea (infants, children, adolescents, and adults: 3% to 5%), vomiting (infants: 6%), xerostomia (3%)

Genitourinary: Urinary tract infection (children: 4%)

Infection: Parasitic infection (children: 3%), varicella zoster infection (children: 4%)

Nervous system: Dizziness (4%), drowsiness (infants: 9%), emotional lability (children: 3%), fatigue (2% to 5%), insomnia (infants: 5%)

Neuromuscular & skeletal: Myalgia (3%)

Respiratory: Bronchitis (infants: 6%), epistaxis (children: 3%), pharyngitis (infants, children, adolescents, and adults: 3% to 5%)

Postmarketing (any population):

Cardiovascular: Palpitations, tachycardia

Dermatologic: Pruritus, skin rash

Hepatic: Hepatitis, increased liver enzymes (including increased serum bilirubin)

Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)

Nervous system: Movement disorder (including dystonia, extrapyramidal reaction, tic disorder), psychomotor agitation, seizure

Respiratory: Dyspnea

Contraindications

Hypersensitivity to desloratadine, loratadine, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported with use; discontinue therapy immediately with signs/symptoms of hypersensitivity.

Disease-related concerns:

• Hepatic impairment: Use with caution in patients with severe hepatic impairment.

• Renal impairment: Use with caution in patients with severe renal impairment.

Concurrent drug therapy issues:

• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.

Special populations:

• Slow metabolizers: Use with caution in patients known to be slow metabolizers of desloratadine (incidence of side effects may be increased).

Dosage form specific issues:

• Phenylalanine: Some products may contain phenylalanine.

Warnings: Additional Pediatric Considerations

Desloratadine may increase susceptibility to seizures in pediatric patients, particularly in patients with a history of seizure disorders; 1 case series described 4 patients (ages: 5 to 16 years) who experienced seizures after initiation of desloratadine. 3 of the 4 patients had known seizure disorders that were controlled prior to treatment with desloratadine. The final patient, who developed absence seizures after initiation of desloratadine, had a family history of febrile seizures but no personal history of seizure disorder (Cerminara 2013).

Safety and efficacy for the use of cough and cold products in pediatric patients <4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).

Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Clarinex: 5 mg [contains corn starch, fd&c blue #2 (indigo carm) aluminum lake]

Clarinex: 5 mg [DSC] [contains fd&c blue #2 (indigo carm) aluminum lake]

Generic: 5 mg

Tablet Disintegrating, Oral:

Generic: 2.5 mg, 5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablet, orally-disintegrating (Desloratadine Oral)

2.5 mg (per each): $5.83

5 mg (per each): $5.83

Tablets (Clarinex Oral)

5 mg (per each): $10.07

Tablets (Desloratadine Oral)

5 mg (per each): $5.02 - $8.69

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Pediatric

Oral: May administer without regard to food.

Orally-dissolving tablet: Place orally-dissolving tablet directly on the tongue; tablet will disintegrate immediately; may be taken with or without water. Take immediately after removing from blister package.

Syrup: A commercially available measuring dropper or syringe calibrated to deliver 2 mL or 2.5 mL should be used to administer appropriate dose.

Administration: Adult

May be taken with or without food.

Orally disintegrating tablets should be placed on the tongue; tablet will disintegrate immediately. Take immediately after removing from blister package. Allow tablet to dissolve completely before swallowing. May be taken with or without water.

Storage/Stability

Tablet, orally disintegrating: Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 85°F). Protect from moisture and excessive heat. Use orally disintegrating tablet immediately after opening blister package.

Use

Symptomatic relief of nasal and non-nasal symptoms of perennial allergic rhinitis (FDA approved in ages ≥6 months and adults); symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (FDA approved in ages ≥2 years and adults); symptomatic relief and reduction in number and size of hives in chronic idiopathic urticaria (FDA approved in ages ≥6 months and adults).

Medication Safety Issues
Sound-alike/look-alike issues:

Clarinex may be confused with Celebrex

Metabolism/Transport Effects

Substrate of CYP2C8 (major), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider therapy modification

Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. Risk C: Monitor therapy

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Desloratadine. Risk C: Monitor therapy

CYP2C8 Inhibitors (Strong): May increase the serum concentration of Desloratadine. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Risk X: Avoid combination

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Food Interactions

Food does not affect bioavailability.

Dietary Considerations

Some products may contain phenylalanine.

Pregnancy Considerations

Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Second generation antihistamines may be used for the treatment of allergic rhinitis and urticaria during pregnancy; however, information related to the use of desloratadine in pregnancy is limited and other medications may be preferred (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).

Monitoring Parameters

CNS symptoms including sedation.

Mechanism of Action

Desloratadine, a major active metabolite of loratadine, is a long-acting tricyclic antihistamine with selective peripheral histamine H1-receptor antagonistic activity.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Within 1 hour.

Duration: 24 hours.

Distribution: Vd: ~49 L/kg (Devillier 2008).

Protein binding: Desloratadine: 82% to 87%; 3-hydroxydesloratadine (active metabolite): 85% to 89%.

Metabolism: Hepatic to active metabolite, 3-hydroxydesloratadine (specific enzymes not identified); subsequently undergoes glucuronidation. Decreased in slow metabolizers of desloratadine.

Half-life elimination:

Children 2 to 5 years: Mean: 16.4 hours (Gupta 2007).

Children 6 to 11 years: Mean: 19.4 hours (Gupta 2007).

Adults: ~27 hours.

Time to peak:

Children 2 to 5 years: Mean: 3.17 hours (range: 1.5 to 8 hours) (Gupta 2007).

Children 6 to 11 years: Mean: 3.57 hours (range: 4 to 12 hours) (Gupta 2007).

Adults: ~3 hours.

Excretion: Urine (41% of radioactive dose); feces (47% of radioactive dose) (Devillier 2008).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: AUC and Cmax are increased.

Hepatic function impairment: AUC and half-life are increased.

Pediatric: Systemic exposure in children (based on AUC and Cmax) is similar to adults (Gupta 2007).

Older adult: Cmax and AUC are 20% higher. The half-life is 33.7 hours.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Actilor | Aeriallerg | Aerius | Deslarex | Desloxan | Dora | Glendes | Hisdine | Lorius;
  • (AR) Argentina: Aerius | Azomyr | Delorat | Desaler | Deslo | Desloramar | Desloratadina richet | Frenaler | Hexaler | Novo Alerpriv | Predualergin | Teralmina;
  • (AT) Austria: Aerius | Dasselta | Desloraderm | Desloratadin | Desloratadin actavis | Desloratadin Genericon | Desloratadin Pluspharma | Desloratadin ratiopharm | Desloratadin Sandoz | Desloratadin stada | Desloratadine ratiopharm;
  • (AU) Australia: Apohealth desloratadine | Blooms the chemist desloratadine | Claramax | Desonex | Priceline pharmacy hayfever & allergy relief;
  • (BD) Bangladesh: Adlorin | Aloran | Aslor | Clarex | Deen | Delorin | Delosia | Delot | Delotad | Derat | Des | Desatrol | Deslona | Deslor | Deslorin | Deslosil | Desmark | Desmin | Desodin | Desolet | Desotem | Destacin | Destin | Dora | Isodin | Momento | Neocilor | Orinex | Relergy | Sarinex | Sedno;
  • (BE) Belgium: Aerius | Desloratadine ab | Desloratadine actavis | Desloratadine Apotex | Desloratadine EG | Desloratadine krka | Desloratadine sandoz | Desloratadine Teva;
  • (BF) Burkina Faso: Aerius | D lor | Deslatyne | Deslor | Deslora denk | Erlus | Rodera;
  • (BG) Bulgaria: Aerius | Desloratadin Zentiva | Desloratadine alvogen | Desloratadine ratiopharm | Desloratadine sopharma | Desybel | Flynise | Jovesto;
  • (BR) Brazil: Aleradina | Aloff | Aloff xpe | Aviant | Desalex | Deslin | Deslorana | Desloratadina | Destadin | Esalerg | Histabloc | Leg | Sigmaliv;
  • (CH) Switzerland: Aerius | Desloratadin actavis | Desloratadin axapharm | Desloratadin helvepharm | Desloratadin Mepha | Desloratadin Sandoz | Desloratadin spirig hc;
  • (CI) Côte d'Ivoire: Aerius | Akerol | Allergus | Delevon | Deller | Deslogen | Desloratadine generis | Desloratadine sp | Doxafin | Dyldes | Erlus | Histadius;
  • (CL) Chile: Aerius | D histaplus | Despeval | Despex | Lotadin | Mailen | Neo alledryl | Neo-claritine | Neoclaritine | Rinofilax;
  • (CN) China: Aerius | Bei xue | Di heng sai | Fu bi ding | Xin min ting;
  • (CO) Colombia: Aerius | Alergus | Amerotadina | Cristhaler | Desalex | Desinista | Deslair | Desler | Deslodex | Desloran | Desloratadina | Desloratadina Genfar | Desloratadina La Sante | Desloratadina mk | Desloratamin | Deslorina | Deslosher | Desloweid | Deslox | Desna | Dexio | Expodes | Ezcloren d | Flaxerd | Gamorvan | Globistamin d | Histaline | Impodina | Lopidex | Lorad | Mailen | Newtarpan | Oxiclarine | Prilex | Renilax | Respimar | Riniloran | Rinotadin | Sidres | Sin alergyn | Sinnaller | Sinuxgen | Zeraller | Zeraller vsff;
  • (CZ) Czech Republic: Aerius | Azomyr | Dasmini | Dasselta | Delesit | Desloratadin +pharma | Desloratadin apotex | Desloratadin aurovitas | Desloratadin krka | Desloratadin mylan | Desloratadin stada | Desloratadin xantis | Desloratadin Zentiva | Desloratadine actavis | Desloratadine glenmark | Desloratadine Teva | Geslora | Jovesto | Lotera;
  • (DE) Germany: Aerius | Dasselta | Deslopuren | Deslora denk | Desloraderm | Desloradia | Desloratadin | Desloratadin actavis | Desloratadin adgc | Desloratadin AL | Desloratadin aristo | Desloratadin axunio | Desloratadin glenmark | Desloratadin heumann | Desloratadin Hexal | Desloratadin hormosan | Desloratadin ratiopharm | Desloratadin stada | Desloratadine puren | Desloratadine ratiopharm | Lorano pro;
  • (DO) Dominican Republic: Aerius | Alerpred | Desarius | Desloratadina | Desloratadina calox | Desloratadina Sandoz | Despeval | Dexio | Esparflin | Lestacan | Lorax | Maxaire | Novo Alerpriv | Ubrile;
  • (EC) Ecuador: Alertan | Aviant | Azomyr | D histaplus | Delorat | Desler | Desloran | Desloratadina | Desloratadina La Sante | Desloratadina mk | Despex | Dexio | Mailen | Neolarmax | Rinofilax;
  • (EE) Estonia: Aerius | Dasselta | Desloratadine sandoz | Desloratadine Zentiva | Yosqiero;
  • (EG) Egypt: Aerius | Alergaway | Allergaway | Delarex | Delora stop | Desa | Deslorastamine | Deslorat | Deslorex | Embanodex | Endstamine | Fernilar | Hygi-tadine | Lorafast | Nouvonase | Stimloric | Tendratine;
  • (ES) Spain: Aerius | Azomyr | Dasselta | Desloratadina | Desloratadina actavis | Desloratadina almus | Desloratadina alter | Desloratadina apotex | Desloratadina Cinfa | Desloratadina combix | Desloratadina Kern | Desloratadina krka | Desloratadina Mylan | Desloratadina normon | Desloratadina pensa | Desloratadina pharmagenus | Desloratadina Qualigen | Desloratadina ranbaxy | Desloratadina Sandoz | Desloratadina stada | Desloratadina tarbis | Desloratadina Tecnigen | Desloratadina teva | Desloratadina vir;
  • (ET) Ethiopia: Aria des | Deslora denk | Deslorat | Desrinal | Destacure | Eslotin;
  • (FI) Finland: Aerius | Caredin | Dasselta | Desloratadin orion | Desloratadin stada | Desloratadine actavis | Desloratadine mylan | Desloratadine ratiopharm | Desloratadine Teva | Deslox | Flynise | Kevenix;
  • (FR) France: Aerius | Dasselta | Desloratadine actavis | Desloratadine almus | Desloratadine arrow | Desloratadine biogaran | Desloratadine Cristers | Desloratadine EG | Desloratadine evolugen | Desloratadine GNR | Desloratadine krka | Desloratadine mylan | Desloratadine phr | Desloratadine Ranbaxy | Desloratadine sandoz | Desloratadine Teva | Desloratadine vj pharm | Desloratadine Zentiva;
  • (GB) United Kingdom: Desloratadine Teva | Neoclarityn;
  • (GR) Greece: Aerius | Neoclarityn | Pylodes | Rhinohelp | Rinispes;
  • (HK) Hong Kong: Aerius | Deslorin | Destavell;
  • (HR) Croatia: Aerius | Alerdin | Dasselta | Desloratadin actavis | Desloratadine Teva | Deslordis | Escontral;
  • (HU) Hungary: Aerius | Alvotadin | Azomyr | Desaero | Desloratadine actavis | Desloratadine mylan | Desloratadine ratiopharm | Desloratadine Stada | Desloratadine Teva | Deslorep | Esradin | Inaller | Lordestin | Lordestin akut;
  • (ID) Indonesia: Aerius | Aleros | Desdin | Deslotine | Destavell | Eslor;
  • (IE) Ireland: Dasselta | Deslor | Neoclarityn;
  • (IL) Israel: Aerius;
  • (IN) India: Alenix | Alerdain | Alerta d | Allerde | D lorinol | D-loratin | Dazit | Delorta | Deltar | Des-od | Desent | Deslor | Desnova | Desobit | Desogold | Deswin | Dexly | Dezlin | Dezlorid | Dyl | Dyl d | Eslot | Lorday | Loreta | Nelora | Neoloridin | Nucope | Otrivin-alert | Rodera | Tastylora;
  • (IS) Iceland: Aerius;
  • (IT) Italy: Aerius | Azomyr | Dasselta | Desloratadina | Desloratadina actavis | Desloratadina aurobindo | Desloratadina doc generici | Desloratadina EG | Desloratadina mylan pharma | Desloratadina pensa | Desloratadina ratiopharm | Desloratadina Sandoz | Desloratadina Zentiva | Efestad;
  • (JO) Jordan: Aeriallerg | Aerius | Deslora | Dislara | Histacare | Lorius | Noura;
  • (JP) Japan: Desalex;
  • (KE) Kenya: Aerius | D lor | D lorat | Dazit | Desafe | Deselex | Deslatyne | Deslora denk | Deslorin | Deslot | Desodin | Neocilor | Neolor;
  • (KR) Korea, Republic of: Aerius;
  • (KW) Kuwait: Actilor | Aerius | Iris;
  • (LB) Lebanon: Aeriallerg | Aerius | Dareq | Deline | Desloratadine arrow | Desloratadine normon | Eslorat | Oradus | Rina;
  • (LT) Lithuania: Aerius | Dasselta | Desloratadina Kern Pharma | Desloratadine Rph | Desloratadine sopharma | Rodispes;
  • (LU) Luxembourg: Aerius | Desloratadine EG;
  • (LV) Latvia: Aerius | Dasselta | Desloratadine actavis | Desloratadine aurovitas | Desloratadine sopharma;
  • (MA) Morocco: Aerius | Destec | Desyal | Erlus | Lodes | Loreus;
  • (MX) Mexico: Abrunt | Aviant | Azomyr | Bennet | Blotamin | Degortrina | Deslibal | Desloratadina | Desloratadina landsteiner | Gronase | Histapharm | Kajuva | Liberdux | Lideater | Lirudine | Selectaler | Sensidex | Tadocil | Urtisin lam | Valgab;
  • (MY) Malaysia: Aerius | Ajalorin | Avorius | Desloratadine sandoz | Deslova | Dezal | Glendes | Synerrv desloratadine;
  • (NG) Nigeria: Delora stop | Hayvent | Mairex | Momento;
  • (NL) Netherlands: Aerius | Dasselta | Desloratadine 2,5 mg focus | Desloratadine ratiopharm | Desloratadine Teva | Neoclarityn;
  • (NO) Norway: Aerius | Caredin;
  • (NZ) New Zealand: Claramax;
  • (PE) Peru: Aerius | Aviant | D'Ventil | Desloglob | Desloramina | Desloran | Deslorat | Desloratadina | Deslortin | Letizia | Lomed | Loralergan | Nafolix | Neoclarityne | Neolarmax | Rinodual | Rinofilax | Ryna del | Vitallerg;
  • (PH) Philippines: Aerius | Allergon | Aroled | Deslo | Deslodine | Deslogen | Deslorastal | Genodes | Neo loridin | Sarinex;
  • (PK) Pakistan: Agenor | Alenor | Alldes | Aloret | Altadine | Antimin d | Arozid | D lor | D next | Delergic | Dellerge | Delomat | Delorta | Delorvin | Delot | Deltafast | Des loratlax | Des-od | Desatil | Desbro | Descover | Desdine | Desgen | Deslet | Deslin | Deslo | Deslofn | Deslorat | Deslort | Deslotin | Deslozon | Desmed | Desnova | Deso l | Desora | Desotin | Destazine | Destidine | Destina | Detora | Dexio | Dictrin | Dinestin | Dingo | Distamin | Doara | Dyl | Eslod | Eslor | Genelor | Histanil D | Jardin d | Kadisdin | Larinex | Lewdes | Lorades | Mdisin | Neo antial | Neolor | Neulorax | Retoret | Selora | Softin od | Weltol;
  • (PL) Poland: Aerius | Alerdes | Alergo max | AlergoTeva | Aleric deslo | Aleric deslo active | Azomyr | Clarderin | Dasselta | Dehistar | Delortan | Delortan allergy | Desada | Deslodyna | Desloratadine +pharma | Desloratadine actavis | Desloratadine aurovitas | Desloratadine dr.max | Desloratadine genoptim | Desloratadine mylan | Desloratadyna apotex | Dynid | Dynid gem | Flynise | Goldesin | Goldesin alerstop | Hitaxa | Hitaxa fast | Jovesto | Pylodes | Suprodeslon | Symdes | Teslor;
  • (PR) Puerto Rico: Clarinex;
  • (PT) Portugal: Aerius | Azomyr | Desloratadina actavis | Desloratadina alter | Desloratadina Aristo | Desloratadina aurobindo | Desloratadina aurovitas | Desloratadina azevedos | Desloratadina Basi | Desloratadina Bluepharma | Desloratadina ciclum | Desloratadina Cinfa | Desloratadina generis | Desloratadina krka | Desloratadina labesfal | Desloratadina mepha | Desloratadina Mylan | Desloratadina ratiopharm | Desloratadina teva;
  • (PY) Paraguay: Alergicap | Desloradex | Despeval | Despex | Lomed | Loner | Mailen | Megadesaler fb | Neo alledryl | Recardex | Supraler;
  • (RO) Romania: Aerius | Dasselta | Desloratadina actavis | Desloratadina alvogen | Desloratadina amring | Desloratadina aurobindo | Desloratadina Sandoz | Desloratadina terapia | Desloratadina teva | Dynid | Lordestin;
  • (RU) Russian Federation: Aerius | Blogir 3 | Delorsin | Desal | Desloratadin | Desloratadine canon | Desloratadine Teva | Desloratadine vertex | Elizey | Eslontin | Ezlor | Lordestin | Nalorius;
  • (SA) Saudi Arabia: Aerius | Deslin | Deslor | Destamin | Iris | Loreta | Lorinex | Neorin | Rina;
  • (SE) Sweden: Aerius | Caredin | Dasselta | Desloratadin ABECE | Desloratadin Apofri | Desloratadin mylan | Desloratadin stada | Desloratadine actavis | Desloratadine glenmark | Desloratadine ratiopharm | Desloratadine sandoz | Desloratadine Teva | Flynise;
  • (SG) Singapore: Aerius | Desalex | Desloratadine sandoz;
  • (SI) Slovenia: Aerius | Dasselta | Desloratadin ratiopharm | Lentrica;
  • (SK) Slovakia: Aerius | Azomyr | Dasselta | Dasseltino | Delesit | Deslomed | Desloratadin saneca | Desloratadin Zentiva | Desloratadine actavis | Desloratadine glenmark | Geslora | Jovesto | Lotera | Spirabel;
  • (TH) Thailand: Aerius | Desloratadine sandoz | Lorius;
  • (TN) Tunisia: Aerius | Allergus | Clarius | Deslor | Desloryne | Histam | Lorinex;
  • (TR) Turkey: Aerius | Alores | Alrinast | Aria des | Deloday | Deslodin | Desloran | Desrinal | Dicomex | Doranit | Doxafin | Eslotin | Lordes;
  • (TW) Taiwan: Denosin | Desdin | Desora;
  • (UA) Ukraine: Aerius | Alerdes | Alernova | Alersis | Allergomax | Allergostop | Astria | Desloratadine astrapharm | Desorus | Dezradin | Edem | Elehius | Elizium | Eridez darnitsa | Eslotin | Fribris | Hitaxa | Loratek | Lordes;
  • (UG) Uganda: Aerius | Alrinast | Deslora denk | Deslorat | Lorfact d | Neo loridin;
  • (UY) Uruguay: Aerius | Cripan | Delorat | Desloratadina Icu Vita | Desloratadina teva | Dislen | Mailen | Mailen rapid;
  • (VE) Venezuela, Bolivarian Republic of: Aerius | Bio Desloratadine | Desalex | Desler | Deslorat | Desloratadina | Deslorin | Deslort | Esparflin | Gamorvan | Histaler | Liberdux | Ofanex | Ventus;
  • (ZA) South Africa: Acuhist | Adco desloratadine | Aerius | Aerzit | Clarex | Desaway | Deselex | Desodene | Desotab | Loralex | Neoclarityne | Neoloridin | Pollentyme nd;
  • (ZM) Zambia: Aerius | D lor | Rodera
  1. Aerius (desloratadine) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; May 2019.
  2. Aerius (desloratadine) [prescribing information]. Haarlem, Netherlands: Merck Sharp & Dohme; October 2018. https://www.ema.europa.eu/en/documents/product-information/aerius-epar-product-information_en.pdf.
  3. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  4. American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
  5. Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed November 23, 2021.
  6. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036 [PubMed 24766875]
  7. Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958. [PubMed 28602936]
  8. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. J Am Acad Dermatol. 2014;70(3):417.e1‐e427. doi:10.1016/j.jaad.2013.09.009 [PubMed 24528912]
  9. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  10. Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(1):1-4. [PubMed 17218934]
  11. Cerminara C, El-Malhany N, Roberto D, Lo Castro A, Curatolo P. Seizures induced by desloratadine, a second-generation antihistamine: clinical observations. Neuropediatrics. 2013;44(4):222-224. [PubMed 23456992]
  12. Cicardi M, Aberer W, Banerji A, et al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. doi:10.1111/all.12380 [PubMed 24673465]
  13. Clarinex (desloratadine) [prescribing information]. Jersey City, NJ: Organon LLC; August 2022.
  14. Desloratadine orally disintegrating tablets [prescribing information]. Bachupally, India: Dr Reddy's Laboratories Limited; March 2019.
  15. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-230. doi:10.2165/00003088-200847040-00001 [PubMed 18336052]
  16. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511.e41. [PubMed 29103802]
  17. Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm. Last accessed November 2, 2018.
  18. Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm. Last accessed November 2, 2018.
  19. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001;107(4):751-762. doi: 10.1067/mai.2001.114239. [PubMed 11295678]
  20. Gupta S, Khalilieh S, Kantesaria B, Banfield C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol. 2007;63(5):534-540. [PubMed 17488362]
  21. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  22. James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. Expert Opin Pharmacother. 2017;18(3):253-262. doi:10.1080/14656566.2017.1282461 [PubMed 28081650]
  23. Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 23, 2021.
  24. McClellan K, Jarvis B. Desloratadine. Drugs. 2001;61(6):789-796. [PubMed 11398910]
  25. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. [PubMed 25711134]
  26. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017;47(7):856-889.
  27. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1 suppl):S1-S43. [PubMed 25644617]
  28. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  29. Staevska, M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676-682. [PubMed 20226302]
  30. Trautmann A, Anders D, Stoevesandt J. H1-Antihistamine Premedication in NSAID-Associated Urticaria. J Allergy Clin Immunol Pract. 2016;4(6):1205-1212. [PubMed 27372601]
  31. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. [PubMed 29336054]
  32. Zuraw B. An overview of angioedema: clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 29, 2022.
Topic 13211 Version 358.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟